PTGX Stock News & Catalysts – Protagonist Therapeutics

FEATURED

Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update

MIMRYLO™ (rusfertide) Approved by FDA for the Treatment of Erythrocytosis in Adults with Polycythemia Vera; Approval Triggered $275 Million in Payments to ProtagonistComprehensive Phase 2b Program with PN-881, an Oral

Summary

Nov 5, 2026, 4:05 PM ·ACCESS Newswire

RECENT

Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026

NEWARK, CA / ACCESS Newswire / October 27, 2026 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that senior management will participate in four investment bank

Oct 27, 2026, 7:00 AM ·ACCESS Newswire

A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday

NEW YORK, Oct. 20, 2026 /CNW/ -- Market Updates News Commentary - Two unrelated announcements on Monday put one of biotech's smaller corners in the spotlight. A company developing a treatment for a rare

Oct 20, 2026, 8:59 AM ·PRNewswire

Protagonist Therapeutics Announces $300 Million Share Repurchase Program

NEWARK, CA / ACCESS Newswire / September 8, 2026 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the Company may

Sep 8, 2026, 4:05 PM ·ACCESS Newswire

Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026

NEWARK, CA / ACCESS Newswire / September 2, 2026 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive

Sep 2, 2026, 7:05 AM ·ACCESS Newswire

Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera

MIMRYLO™ is the First and Only Hepcidin Mimetic Peptide Therapy Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera, Offering a Novel Mechanism to Maintain Hematocrit Control, Meaningfully

Aug 28, 2026, 8:30 PM ·ACCESS Newswire

Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / August 18, 2026 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported that on August 17, 2026, it granted inducement awards to two recently hired employees in accordance with the

Aug 18, 2026, 4:05 PM ·ACCESS Newswire

Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ICOTYDE™ First Full Quarter of Commercial Sales with Strong Early AdoptionRusfertide NDA under Priority Review for Polycythemia Vera; PDUFA Date in August 2026Comprehensive Phase 2b Program with PN-881, an Oral IL-17

Aug 5, 2026, 4:05 PM ·ACCESS Newswire

Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / August 4, 2026 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported that on July 31, 2026, it granted inducement awards to two recently hired employees in accordance with the

Aug 4, 2026, 4:05 PM ·ACCESS Newswire

Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / July 16, 2026 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported that on July 15, 2026, it granted inducement awards to three recently hired employees in accordance with the

Jul 16, 2026, 4:05 PM ·ACCESS Newswire

Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / July 1, 2026 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported that on June 30, 2026, it granted inducement awards to three recently hired employees in accordance with the

Jul 1, 2026, 4:05 PM ·ACCESS Newswire

Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / June 16, 2026 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported that on June 15, 2026, it granted inducement awards to three recently hired employees in accordance with the

Jun 16, 2026, 4:00 PM ·ACCESS Newswire

Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress

NEWARK, CA / ACCESS Newswire / June 1, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that four abstracts highlighting rusfertide in polycythemia vera (PV) will be presented at the

Jun 1, 2026, 7:05 AM ·ACCESS Newswire

Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026

NEWARK, CA / ACCESS Newswire / May 28, 2026 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate

May 28, 2026, 7:05 AM ·ACCESS Newswire

Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update

ICOTYDE™ (icotrokinra) approved by FDA in March for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment; Protagonist receives tiered royalties of 6% to 10% and is eligible for up to $580

May 5, 2026, 4:05 PM ·ACCESS Newswire

Protagonist Therapeutics, Inc. PTGX · News